pGDC59 Biomarker Identifies Pregnancy-Induced Glucose Intolerance

One biomarker measurement during pregnancy can identify glucose intolerance with high sensitivity and specificity.
One biomarker measurement during pregnancy can identify glucose intolerance with high sensitivity and specificity.

HealthDay News — One measurement of plasma glycated CD59 (pGCD59) in pregnancy can predict glucose intolerance, according to a study published online in Diabetes Care.

Pamela Ghosh, PhD, from Brigham and Women's Hospital in Boston, and colleagues conducted a case-control study of 1,000 plasma samples from women receiving standard prenatal care. Five hundred women had a normal glucose challenge test (GCT) for screening of gestational diabetes (GDM), and 500 had a failed GCT and had a subsequent oral glucose tolerance test (control subjects and case patients, respectively).

The researchers found that the median pGCD59 value was 8.5-fold higher in case patients and 10-fold higher in GDM patients compared with controls: 0.33, 2.79, and 3.23, respectively (P <.001). The area under the receiver operating characteristic curve was 0.92. The prevalence of large for gestational age (LGA) was 4.3% and 13.5^ in the lowest and highest quartiles of pGCD59, respectively.

"One pGCD59 measurement during weeks 24 to 28 identifies pregnancy-induced glucose intolerance with high sensitivity and specificity and can potentially identify the risk for LGA," the authors write.

Two authors disclosed a financial interest in Mellitus, which is developing diagnostic tools for diabetes.

Reference

Ghosh P, Luque-Fernandez MA, Vaidya A, et al. Plasma glycated CD59, a novel biomarker for detection of pregnancy-induced glucose intolerance [published online May 3, 2017]. Diabetes Care. doi: 10.2337/dc16-2598

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters